Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

People with diabetes may have another reason to protect their cardiovascular health

30

Aug 2026

People with diabetes may have another reason to protect their cardiovascular health

Better cardiovascular health, measured using Life’s Essential 8, was associated with a lower risk of mild cognitive impairment among people with diabetes after accounting for genetic susceptibility. Associations with dementia varied by genetic risk, while higher LE8 scores were also linked to greater gray matter volume and lower white matter hyperintensity volume.

Your skin may offer clues about how many fruits and vegetables you eat

30

Aug 2026

Your skin may offer clues about how many fruits and vegetables you eat

In an exploratory study of 137 Australian adults, skin yellowness measured by reflectance spectroscopy was associated with combined fruit and vegetable intake, fruit intake alone, total carotenoid intake, body fat percentage and skin color. The findings suggest skin measurements could provide an objective dietary biomarker, but the researchers caution that skin color, ethnicity and other individual characteristics may influence how the measurements are interpreted.

Breast cancer survivors could avoid lifelong heart medication, research suggests

30

Aug 2026

Breast cancer survivors could avoid lifelong heart medication, research suggests

Many breast cancer survivors whose treatment caused them to develop problems with their heart function can safely stop their medication after their heart recovers and most won't need to continue treatment long-term, according to a study funded by the British Heart Foundation and presented at the European Society of Cardiology Congress in Munich.

SWITCH SWEDEHEART trial shows prasugrel matches ticagrelor with less bleeding

29

Aug 2026

SWITCH SWEDEHEART trial shows prasugrel matches ticagrelor with less bleeding

Prasugrel reduced major cardiovascular events to the same extent as ticagrelor but with lower major bleeding after coronary stenting in patients with acute coronary syndromes, according to results from the SWITCH SWEDEHEART trial presented in a Hot Line session today at ESC Congress 2026 and published simultaneously in the New England Journal of Medicine.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.